Healthy volunteers are narrow evidence
Small, selected groups cannot reveal all uncommon or long-term harms.
Claim investigation · O-029
Peptide muscle-growth and performance claims
A hormone rise is not a performance result. Secretagogues, growth-hormone-releasing factors, IGF-1 analogues and modified growth factors are marketed together, although their mechanisms, evidence and risks differ.
Human studies show that some compounds can change growth hormone or IGF-1 measurements. That does not establish more strength, better endurance, faster recovery or a favourable benefit-risk balance in healthy users. Direct performance evidence is limited, while the 2026 WADA list prohibits the main growth-hormone and growth-factor classes.
The marketed groups are not interchangeable
They act at different points in the growth-hormone and growth-factor system.
| Group | Examples in the topical map | What early human research may measure | Evidence gap |
|---|---|---|---|
| Growth-hormone secretagogues | Ipamorelin and related GHRP or ghrelin-receptor agonists. | Short-term pharmacokinetics and stimulated growth-hormone concentrations. | A hormone pulse does not establish muscle strength or athletic performance. |
| Growth-hormone-releasing factors | CJC-1295 and sermorelin. | Growth-hormone and IGF-1 concentrations in defined research settings. | Healthy performance outcomes and long-term safety remain separate questions. |
| IGF-1 analogues | IGF-1 LR3. | Consumer claims often extrapolate from IGF-1 biology or authorised medicines that are not IGF-1 LR3 products. | Direct controlled evidence for the marketed analogue is lacking. |
| Modified growth factors | MGF and modified forms. | Mainly laboratory and animal mechanisms related to muscle tissue signalling. | Product identity, human outcomes and safety are not established by mechanism. |
Five outcomes that marketing often merges
Growth hormone concentration is a laboratory measurement. IGF-1 concentration is another. Lean body mass is a body-composition measure that can include fluid. Strength is task-specific force production. Performance can involve power, endurance, skill and recovery.
One outcome cannot stand in for the others. A 2008 systematic review of growth hormone in healthy, physically fit people found an increase in lean body mass but no clear improvement in strength or exercise capacity, alongside more soft-tissue oedema and fatigue. That review examined growth hormone, not every peptide named on this page, but it demonstrates why body composition and performance must be separated.
For any compound, look for direct, prespecified, controlled human outcomes rather than a biomarker used as a surrogate.
What the CJC-1295 studies actually establish
Small early studies in healthy adults reported sustained increases in growth hormone and IGF-1 after CJC-1295. These pharmacology findings show biological activity for the studied investigational product. They did not establish improved muscle strength, endurance, competitive performance or the long-term safety of products sold online.
The same transfer limit applies elsewhere. An ipamorelin volunteer study described pharmacokinetics and a growth-hormone response. It was not a muscle-growth trial. A seller cannot turn a laboratory endpoint into a performance outcome by changing the headline.
Why risk cannot be inferred from a short hormone study
Hours or days miss later effects
Brief pharmacology studies do not establish repeated-use safety.
Investigational material is controlled
Online items do not inherit trial manufacture, identity or storage.
Hormone pathways have wide effects
Metabolic, fluid, neurological and tissue-growth consequences need direct monitoring.
Prohibited classes run through this cluster
The 2026 WADA list prohibits growth hormone, its analogues and fragments; growth-hormone-releasing factors and their analogues; growth-hormone secretagogues and mimetics; and IGF-1 and its analogues. It also names mechano growth factors and other growth factors affecting muscle, tendon, ligament or protein synthesis.
Read what this means if you compete. Strict liability and uncertain product composition make label ambiguity a risk, not a defence.
Follow the compound records
Each link preserves the difference between the marketed product and the evidence actually available.
Group recordThe secretagogue group comparedSeparate receptor agonists, human biomarker data and claim transfer.
Growth-factor analogueIGF-1 LR3 and its distinct risksDo not borrow evidence from authorised IGF-1 medicines.
Releasing factorThe CJC-1295 evidenceWhat its early human studies measured and left unknown.
Releasing factorThe sermorelin positionHistory, regulatory status and evidence boundaries.
Modified growth factorMGF and its modified formsMechanism claims, identity questions and human-evidence gaps.
How we assessed this claim
We separated mechanism, hormone concentration, body composition, strength and performance. We matched each paper to the named compound and formulation, then checked whether the population and outcome answered the consumer claim. We treated anti-doping classification and product identity as separate, consequential questions. We did not infer a performance benefit from a laboratory marker or a product’s printed amount.
Source ledger
Primary and peer-reviewed sources checked on 7 August 2026.
- CJC-1295 growth hormone and IGF-1 study · early human pharmacology, not a performance trial.
- CJC-1295 pulsatile growth-hormone study · hormone secretion and IGF-1 endpoints in healthy adults.
- Ipamorelin pharmacokinetic and pharmacodynamic study · growth-hormone response in healthy volunteers.
- Systematic review of growth hormone and athletic performance · controlled human evidence distinguishing lean mass from strength and exercise capacity.
- World Anti-Doping Agency 2026 Prohibited List · current growth-hormone, releasing-factor, secretagogue, IGF-1 and growth-factor classes.
Questions people ask
Do peptide secretagogues build muscle?
Some secretagogues can increase growth-hormone measurements in short human studies. That does not prove a meaningful increase in muscle strength, power, endurance or recovery. Those outcomes require direct controlled trials and adequate safety follow-up.
Does a higher IGF-1 level prove better performance?
No. IGF-1 is a biomarker within a complex pathway. A change in concentration does not establish improved strength or competition performance, and it does not show that benefits outweigh metabolic, fluid or tissue-growth risks.
Are CJC-1295 and ipamorelin proven performance enhancers?
Early human studies show that the studied compounds can alter growth-hormone or IGF-1 measurements. They do not establish reliable athletic-performance gains, long-term safety or the identity and quality of consumer products sold under those names.
Are growth-hormone peptides prohibited by WADA?
The 2026 list prohibits growth-hormone-releasing factors, secretagogues and mimetics, as well as IGF-1 and relevant growth factors. Athletes should check the exact current list and seek appropriate anti-doping advice.
Editorial experience
From our work: how we checked this page
For topical-map item O-029, Peptide muscle-growth and performance claims was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 5 unique external sources and 9 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.